Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 64
- Registration Number
- NCT02411344
- Locations
- 🇮🇹
Policlinico Vittorio Emanuele, Catania, CT, Italy
🇮🇹A. O. U. Santa Maria della Misericordia, Udine, UD, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, MI, Italy
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Otto Metzger, MD
- Target Recruit Count
- 68
- Registration Number
- NCT02390427
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Fasting on Newly Diagnosed Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT02379585
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 86
- Registration Number
- NCT02339532
- Locations
- 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷Institut de Cancerologie de L'Ouest - Site Paul Papin, Angers, France
🇫🇷Centre Hospitalier Regional Universitaire de Brest - Hôpital Morvan, Brest, France
A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
- Conditions
- Interventions
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
- Conditions
- Interventions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 164
- Registration Number
- NCT02326974
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Tennessee Oncology/Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 154
- Registration Number
- NCT02320435
- Locations
- 🇫🇷
Centre Henri Becquerel; Oncologie Medicale, Rouen, France
🇫🇷Centre Georges Francois Leclerc; Oncologie 3, Dijon, France
🇫🇷Clinique Armoricaine Radiologie; Cons Externes, Saint Brieuc, France
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1044
- Registration Number
- NCT02291289
- Locations
- 🇦🇷
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología, Buenos Aires, Argentina
🇧🇪Institut Jules Bordet X, Brussels, Belgium
🇧🇪Hospital Erasme, Bruxelles, Belgium
Observational Study of Pertuzumab Safety in Participants With Breast Cancer
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT02266173
- Locations
- 🇰🇷
Inje university Haeundae Paik Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.